article thumbnail

CCC Now Offering Subscriptions to the JAMA Network and The New England Journal of Medicine Through RightFind

Copyright Clearance Center

NEJM is pleased to participate in an innovative new service from CCC that aligns with our goal to meet the information needs of researchers for the highest quality studies in medical science,” said Rob McKinney, Director, NEJM Group Licensing.

article thumbnail

Amgen and Pfizer appoint new Science executives

European Pharmaceutical Review

In his over 11-year tenure at Pfizer thus far, Dr Boshoff he has delivered 24 approved innovative medicines and biosimilars in over 30 indications, according to Pfizer. “Dr He trained as medical oncologist at the Royal Marsden and Royal Free Hospitals in London. Academy of Medical Sciences. “I

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Life sciences response to 2024 Autumn Budget

European Pharmaceutical Review

It pledges to benefit key industry sectors across life sciences including R&D, innovation, manufacturing and medicine. Therefore, to safeguard future economic growth, “the opportunity is now” for science, medicine and R&D sectors to take advantage of what the Autumn Budget has to offer, signals Todd.

article thumbnail

The Role of Medical Science Liaisons in The Pharmaceutical Industry

Contrarian Sales Techniques

Are you ready to explore the fascinating world of Medical Science Liaisons (MSLs) in the pharmaceutical industry ? MSLs are considered the experts in scientific and medical information and they are responsible for building relationships with healthcare professionals. The growing demand for MSLs shows no signs of slowing down.

article thumbnail

Artificial Intelligence and Life Expectancy: How AI Will Contribute to Improving Human Health.

MaBiCo

AI applications in medicine, pharmaceuticals, and biology promise to bring about radical changes, making treatments more effective, personalized, and affordable. Personalized Medicine Thanks to AI, we will create simulations of the human body at the molecular, cellular and organ levels, allowing treatments to be personalized for each patient.

article thumbnail

Progressing personalised cell therapies in oncology

European Pharmaceutical Review

In this Q&A, Dr Imran Khan, PhD, Vice President Medical Affairs, Hematology at Johnson & Johnson Innovative Medicine, highlights the current landscape of CAR T therapies such as CARVYKTI and touches on the future direction of the sector. Most recently, Imran has served as Medical Science Liaison (MSL) Head, Oncology U.S.

article thumbnail

Dapagliflozin approved for heart failure across LVEFs

European Pharmaceutical Review

The Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a licence extension for FORXIGA (dapagliflozin) in Great Britain for symptomatic chronic heart failure (HF) across the full spectrum of left ventricular ejection fraction (LVEF).